AbCellera Completes Antibody Discovery Project With Kodiak Sciences to Identify Lead Therapeutic Candidates
(Thomson Reuters ONE) -
Kodiak exercises option to advance antibody candidates identified by AbCellera
into its clinical development programs.
VANCOUVER, British Columbia, Aug. 24, 2016 (GLOBE NEWSWIRE) -- AbCellera
Biologics Inc., a biotechnology company specializing in the rapid discovery of
monoclonal antibodies from natural immune cells, announced today the successful
completion of its antibody discovery partnership with Kodiak Sciences.
Through this collaboration, AbCellera applied its antibody discovery platform to
perform ultra-deep screening of immunized animals and identified hundreds of
antibodies against an undisclosed target. Multiplexed single cell binding assays
were used to enrich for antibodies with high affinity and desired properties,
resulting in the generation of multiple lead antibody families with picomolar
affinity and potent blocking activity.
Dr. Carl Hansen, CEO and co-founder of AbCellera commented: "AbCellera is
committed to delivering industry-leading antibody discovery to enable and
accelerate partner programs. Our work with Kodiak is a flagship example of our
ability to collaborate effectively with innovative biotech companies. It has
been a pleasure to work with the Kodiak team, and we are grateful for the
opportunity to participate in the advancement of their next-generation
therapies."
"AbCellera has outperformed our expectations," said Dr. Victor Perlroth,
Chairman and CEO of Kodiak Sciences. "AbCellera's technology platform leverages
the many benefits of in vivo selection and maturation while avoiding the
inefficiency of traditional hybridoma approaches. They screened over one million
antibody-producing single cells and delivered relevant antibody sequences
covering a diverse functional and sequence space."
Under the terms of the agreement, Kodiak has executed its option to advance
selected candidates for clinical development with AbCellera eligible to receive
downstream payments. Other financial terms were not disclosed.
About AbCellera Biologics Inc.
AbCellera is a privately held biotechnology company that provides enabling
technologies for the discovery and development of monoclonal antibody (mAb)
therapies directly from natural immune cells.
AbCellera's lead technology is a proprietary single cell antibody discovery
platform that provides pharma and biotech partners with the ability to rapidly
identify mAb therapeutic candidates from the natural immune repertoires of any
species, including humans. For more information, please visit www.abcellera.com.
About Kodiak Sciences Inc.
Kodiak is designing and developing novel therapies for the treatment of retinal
disease. For further information about the company, please
visit www.kodiak.com.
Media Contact
Kevin Heyries
Telephone: 604.827.4151
Email: media(at)abcellera.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AbCellera via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 24.08.2016 - 15:00 Uhr
Sprache: Deutsch
News-ID 490915
Anzahl Zeichen: 3542
contact information:
Town:
Vancouver
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 296 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbCellera Completes Antibody Discovery Project With Kodiak Sciences to Identify Lead Therapeutic Candidates"
steht unter der journalistisch-redaktionellen Verantwortung von
AbCellera (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
